Scholar Rock Holding Corporation (SRRK), a late-stage biopharmaceutical company, Monday said its Phase 3 SAPPHIRE study evaluating ...
Scholar Rock Holding said that its treatment for spinal muscular atrophy met primary endpoint targets in a phase 3 clinical trial. The late-stage biopharmaceutical company said Monday that Apitegromab ...
(Reuters) -Scholar Rock said on Monday its drug apitegromab met the main goal in a late-stage trial which tested it on patients with a type of rare genetic neuromuscular disease. Apitegromab showed ...